R. Palich

Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area

R. Tubiana, C. Katlama, D. Costagliola, 2022, European Journal of Clinical Microbiology & Infectious Diseases.

Long-term follow-up of HIV-infected patients on dolutegravir monotherapy.

R. Tubiana, C. Katlama, G. Peytavin, 2019, The Journal of antimicrobial chemotherapy.

Country of birth is associated with discrepancies in the prescription of two-drug regimens in successfully treated people with HIV in France

L. Cuzin, P. Delobel, L. Hocqueloux, 2023, AIDS.

Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial

C. Katlama, Y. Yazdanpanah, F. Raffi, 2021, AIDS Research and Therapy.

Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.

R. Tubiana, C. Katlama, F. Raffi, 2020, The Journal of antimicrobial chemotherapy.

Birth Country Influences the Choice of Antiretroviral Therapy in HIV-Infected Individuals: Experience From a French HIV Centre

R. Tubiana, C. Katlama, L. Cuzin, 2022, Journal of acquired immune deficiency syndromes.

INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels

V. Calvez, C. Katlama, A. Boyd, 2019, Open forum infectious diseases.

Hepatitis C virus incidence in HIV‐infected and in preexposure prophylaxis (PrEP)‐using men having sex with men

B. Hoen, F. Raffi, P. Pradat, 2018, Liver international : official journal of the International Association for the Study of the Liver.